COVID-19 pandemic challenges: on the way to overcome obstacles in realization of PAH-specific therapy treatment goals

Our observation demonstrates a case of 40-year-old female with idiopathic pulmonary arterial hypertension World Health Organization functional class III, who was admitted to NMRC Cardiology repeatedly due disease progression including dyspnea worsening and exercise tolerance decrease after previous COVID-19 infection on riociguat (7.5 mg daily), macitentan (10 daily) selexipag (1600 mcg therapy. Clinical examination demonstrated high-risk status according the expected 1-year mortality. Due unreleased treatment goals status, we performed transition from inhale iloprost. After therapy escalation patient significant improvement in clinical condition, reduction increase. The current strategy for is based regular multiparametric risk stratification approach PAH patients. impact may become an important cause patients during pandemic. Directed vasodilatation antiproliferation mechanisms action PAH-specific drugs are supposed be protective However, probability despite intake needs closely monitored perform timely correction order achieve low-risk improve prognosis